Article

Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force.

Gérontopôle, Department of Geriatric Medicine, Toulouse University Hospital, Toulouse, France.
The Journal of Nutrition Health and Aging (Impact Factor: 2.39). 01/2009; 13(10):881-9.
Source: PubMed

ABSTRACT The use of a simple, safe, and easy to perform assessment tool, like gait speed, to evaluate vulnerability to adverse outcomes in community-dwelling older people is appealing, but its predictive capacity is still questioned. The present manuscript summarises the conclusions of an expert panel in the domain of physical performance measures and frailty in older people, who reviewed and discussed the existing literature in a 2-day meeting held in Toulouse, France on March 12-13, 2009. The aim of the IANA Task Force was to state if, in the light of actual scientific evidence, gait speed assessed at usual pace had the capacity to identify community-dwelling older people at risk of adverse outcomes, and if gait speed could be used as a single-item tool instead of more comprehensive but more time-consuming assessment instruments.
A systematic review of literature was performed prior to the meeting (Medline search and additional pearling of reference lists and key-articles supplied by Task Force members). Manuscripts were retained for the present revision only when a high level of evidence was present following 4 pre-selected criteria: a) gait speed, at usual pace, had to be specifically assessed as a single-item tool, b) gait speed should be measured over a short distance, c) at baseline, participants had to be autonomous, community-dwelling older people, and d) the evaluation of onset of adverse outcomes (i.e. disability, cognitive impairment, institutionalisation, falls, and/or mortality) had to be assessed longitudinally over time. Based on the prior criteria, a final selection of 27 articles was used for the present manuscript.
Gait speed at usual pace was found to be a consistent risk factor for disability, cognitive impairment, institutionalisation, falls, and/or mortality. In predicting these adverse outcomes over time, gait speed was at least as sensible as composite tools.
Although more specific surveys needs to be performed, there is sufficient evidence to state that gait speed identifies autonomous community-dwelling older people at risk of adverse outcomes and can be used as a single-item assessment tool. The assessment at usual pace over 4 meters was the most often used method in literature and might represent a quick, safe, inexpensive and highly reliable instrument to be implemented.

1 Bookmark
 · 
361 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives To examine the association between statin use and objectively assessed decline in gait speed in community-dwelling older adults.DesignLongitudinal cohort study.SettingHealth, Aging and Body Composition (Health ABC) Study.ParticipantsTwo thousand five participants aged 70–79 at baseline with medication and gait speed data at 1998–99, 1999–2000, 2001–02, and 2002–03.MeasurementsThe independent variables were any statin use and their standardized daily doses (low, moderate, high) and lipophilicity. The primary outcome measure was decline in gait speed of 0.1 m/s or more in the following year of statin use. Multivariable generalized estimating equations were used, adjusting for demographic characteristics, health-related behaviors, health status, and access to health care.ResultsStatin use increased from 16.2% in 1998–99 to 25.6% in 2002–03. The overall proportions of those with decline in gait speed of 0.1 m/s or more increased from 22.2% in 1998 to 23.9% in 2003. Statin use was not associated with decline in gait speed of 0.1 m/s or more (adjusted odds ratio (AOR) = 0.90, 95% confidence interval (CI) = 0.77–1.06). Similar nonsignificant trends were also seen with the use of hydrophilic or lipophilic statins. Users of low-dose statins were found to have a 22% lower risk of decline in gait speed than nonusers (AOR = 0.78, 95% CI = 0.61–0.99), which was mainly driven by the results from 1999–2000 follow-up.Conclusion These results suggest that statin use did not increase decline in gait speed in community-dwelling older adults.
    Journal of the American Geriatrics Society 12/2014; 63(1). DOI:10.1111/jgs.13134 · 4.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract: Physical inactivity (PI) and obesity are risk factors for many health conditions, including knee pain (KP). The purpose of the present study was to examine the 6-year effects of PI and obesity on gait speed (GS) among older adults with frequent KP. This prospective cohort study used data from the Osteoarthritis Initiative (OAI). At baseline, we studied 1788 adults aged 45 to 79 years old. We grouped the participants into four categories according to baseline scores on the Physical Activity Scale for the Elderly (PASE) and body mass index (BMI). GS was measured using the 20-m timed walk test. Frequent KP was assessed with a self-report questionnaire, and obesity was assessed by BMI (30 kg/m2 or greater). General linear mixed models were conducted using data collected at baseline and 12, 24, 36, 48, and 72 months. After adjusting for all covariates, lower levels of physical activity and obesity were associated with a decrease in GS (β = −0.095, SE = 0.011, p < 0.0001). Our results suggest that both PI and obesity are associated with decreased GS over time in older adults with frequent KP.
    International Journal of Environmental Research and Public Health 02/2015; 12(2):1849-1863. DOI:10.3390/ijerph120201849 · 1.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To create and validate a frailty assessment tool for community-dwelling adults aged ≥75 years. Longitudinal, population-based study. The Survey of Health, Ageing and Retirement in Europe (SHARE). 4001 women and 3057 men aged ≥75 years from the second wave of SHARE. 3325 women and 2587 men had complete information for the frailty indicators: fatigue, low appetite, weakness, observed gait (walking without help, walking with help, chairbound/bedbound, unobserved) and low physical activity. The internal validity of the frailty indicators was tested with latent class analysis, by modelling an underlying variable with three ordered categories. The predictive validity of the frailty classification was tested against 2-year mortality and 4-year disability. The mortality prediction of SHARE-FI75+ was compared with that of previously operationalised frailty scales in SHARE (SHARE-FI, 70-item index, phenotype, FRAIL). In both genders, all frailty indicators significantly aggregated into a three-category ordinal latent variable. After adjusting for baseline age, comorbidity and basic activities of daily living (BADL) disability, the frail had an OR for 2-year mortality of 2.2 (95% CI 1.2 to 3.8) in women and 4.2 (2.6 to 6.8) in men. The mortality prediction of SHARE-FI75+ was similar to that of the other SHARE frailty scales. By wave 4, 49% of frail women (78 of 159) had at least one more limitation with BADL (compared with 18% of non-frail, 125 of 684; p<0.001); in men, these proportions were 39% (26 of 66) and 18% (110 of 621), respectively (p<0.001). A calculator is supplied for point-of-care use, which automatically replicates the frailty classification for any given measurements. SHARE-FI75+ could help frailty case finding in primary care and provide a focus for personalised community interventions. Further validation in trials and clinical programmes is needed. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
    BMJ Open 12/2014; 4(12):e006645. DOI:10.1136/bmjopen-2014-006645 · 2.06 Impact Factor

Full-text (2 Sources)

Download
893 Downloads
Available from
May 20, 2014